Diabetic Peripheral Neuropathic Pain (DPNP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Peripheral neuropathic pain (PNP) is a distressing and enduring chronic pain syndrome that can manifest following damage or disease affecting the peripheral somatosensory nervous system or due to drug triggers. PNP causes vary and can be categorized based on whether nerve damage arises from systemic factors like diseases, toxins, or medications or localized secondary effects like trauma, surgery, or cancer. The signs and symptoms of PNP can fluctuate as the disease progresses and can be influenced by the patient's emotional state and anxiety levels. Neuralgias typically exhibit characteristic episodic paroxysms, whereas other neuropathic pains may occur as isolated episodes or as increasing intensity attacks on top of a continuous pain background. Peripheral neuropathy encompasses various types, with risk factors contingent upon the underlying condition or the affected nerves. PNP can either be congenital or develop due to injury or illness. The most prevalent form of peripheral neuropathy is associated with diabetes, affecting approximately 60–70% of diabetic patients. The numerous causes of peripheral neuropathy can be categorized as hereditary, infectious, immunologic, metabolic, mechanical, cancer-related, toxic, or idiopathic. Neuropathic pain syndromes represent chronic pain disorders resulting from nervous system lesions or diseases that typically transmit pain signals. These conditions encompass various situations, including health conditions, specific medications, or trauma. However, in some instances, the cause remains unidentified, termed idiopathic neuropathy. The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) recommends tricyclic antidepressants, gabapentin or pregabalin, and the SNRIs venlafaxine or duloxetine as first-line treatments for neuropathic pain. Second-line options encompass tramadol, topical lidocaine, or high-concentration capsaicin. Strong opioids (Morphine and Oxycodone) and botulinum toxin-A (BTX-A) are included as third-line treatments for peripheral neuropathic pain. Cannabinoids and valproate receive weak recommendations against their use in neuropathic pain. Chronic neuropathic pain is more prevalent in women and individuals over 50, typically affecting areas like the lower back and limbs and the neck and upper limbs.

  • The prevalence of peripheral neuropathy among adults with diabetes varies significantly, estimated to range from 6% to 51%. This wide range is influenced by factors such as age, duration of diabetes, glucose control, and whether the diabetes is type 1 or type 2.

 

Thelansis’s “Diabetic Peripheral Neuropathic Pain (DPNP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Peripheral Neuropathic Pain (DPNP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Diabetic Peripheral Neuropathic Pain (DPNP) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Diabetic Peripheral Neuropathic Pain (DPNP) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Diabetic Peripheral Neuropathic Pain (DPNP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more